Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Anticancer Res ; 44(7): 2989-2995, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38925832

ABSTRACT

BACKGROUND/AIM: To evaluate the association between prophylactic administration of clarithromycin (CAM) and the development of radiation pneumonitis (RP) in patients treated with intensity modulated radiation therapy (IMRT) for lung cancer. PATIENTS AND METHODS: A total of 89 patients who underwent definitive or salvage IMRT for lung cancer were retrospectively evaluated. The median total and daily doses were 60 Gy and 2 Gy, respectively. A total of 39 patients (44%) received CAM for a median of three months after the start of IMRT. The relationship between the development of RP and certain clinical factors was analyzed. RESULTS: RP of Grade ≥2 was recognized in 10 (11%) patients; Grade 2 in six patients and Grade 3 in four patients. The incidence of Grade ≥2 RP was 3% (1/39) in patients treated with CAM, which was significantly lower than that of 18% (9/50) in patients without CAM. The median lung V20 and V5 in the 10 patients with RP Grade ≥2 were 24% and 46%, respectively, compared with 18% and 37% in the 79 patients with RP Grade 0-1, and the differences were significant. Durvalumab administration after IMRT was also a significant factor for RP Grade ≥2. CONCLUSION: Prophylactic administration of CAM may reduce Grade ≥2 RP in patients treated with IMRT for lung cancer. Therefore, further clinical trials are warranted.


Subject(s)
Clarithromycin , Lung Neoplasms , Radiation Pneumonitis , Radiotherapy, Intensity-Modulated , Humans , Clarithromycin/therapeutic use , Male , Female , Radiation Pneumonitis/prevention & control , Radiation Pneumonitis/etiology , Lung Neoplasms/radiotherapy , Lung Neoplasms/pathology , Aged , Middle Aged , Radiotherapy, Intensity-Modulated/adverse effects , Radiotherapy, Intensity-Modulated/methods , Retrospective Studies , Aged, 80 and over , Adult
2.
Cancers (Basel) ; 14(2)2022 Jan 13.
Article in English | MEDLINE | ID: mdl-35053562

ABSTRACT

BACKGROUND: The purpose of this study was to evaluate the efficacy and toxicity of adding regional hyperthermia to intensity-modulated radiotherapy (IMRT) plus neoadjuvant androgen deprivation therapy (ADT) for high-risk localized prostate carcinoma. METHODS: Data from 121 consecutive patients with high-risk prostate carcinoma who were treated with IMRT were retrospectively analyzed. The total planned dose of IMRT was 76 Gy in 38 fractions for all patients; hyperthermia was used in 70 of 121 patients. Intra-rectal temperatures at the prostate level were measured to evaluate thermal dose. RESULTS: Median number of heating sessions was five and the median total thermal dose of CEM43T90 was 7.5 min. Median follow-up duration was 64 months. Addition of hyperthermia to IMRT predicted better clinical relapse-free survival. Higher thermal dose with CEM43T90 (>7 min) predicted improved biochemical disease-free survival. The occurrence of acute and delayed toxicity ≥Grade 2 was not significantly different between patients with or without hyperthermia. CONCLUSIONS: IMRT plus regional hyperthermia represents a promising approach with acceptable toxicity for high-risk localized prostate carcinoma. Further studies are needed to verify the efficacy of this combined treatment.

3.
J UOEH ; 43(3): 355-361, 2021.
Article in English | MEDLINE | ID: mdl-34483195

ABSTRACT

A sufficient dose of radiation is difficult to administer in re-irradiation for local recurrence of cancer after radiotherapy because of the dose limitation to organs at risk. Re-irradiation cases also include radioresistant tumors that are difficult to control locally, and their prognosis is poor in general. The effect of re-irradiation using intensity-modulated radiotherapy (IMRT) has recently been reported to significantly reduce the dose to organs at risk, and the efficacy of hyperthermia has been reported for radioresistant tumors. We report a case of local recurrence after concurrent chemoradiotherapy treated with salvage re-irradiation using IMRT and chemotherapy combined with hyperthermia in a patient with nasopharyngeal carcinoma, and include a discussion of the literature.


Subject(s)
Nasopharyngeal Neoplasms , Radiotherapy, Intensity-Modulated , Re-Irradiation , Chemoradiotherapy , Humans , Hyperthermia , Nasopharyngeal Carcinoma/therapy , Nasopharyngeal Neoplasms/drug therapy , Nasopharyngeal Neoplasms/radiotherapy , Neoplasm Recurrence, Local/therapy , Retrospective Studies
4.
Cancers (Basel) ; 13(5)2021 Feb 26.
Article in English | MEDLINE | ID: mdl-33652744

ABSTRACT

Background: The purpose of this study was to evaluate the effectiveness of the clinical setting for deep regional hyperthermia of an 8 MHz radiofrequency (RF) capacitively coupled device in the pelvis by using numerical simulations of the electromagnetic field. Methods: A three-dimensional patient model of cervical cancer of the uterus in an obese patient was reconstructed with computed tomography data. The specific absorption rate (SAR) and temperature distributions among the various heating settings were evaluated using numerical simulations. Results: The averaged SAR value of the deep target tumor was similar between with or without overlay boluses (OBs), and that of the subcutaneous fat (SF) at the edges of cooling boluses with OBs was lower than that of the SF without OBs. The use of OBs reduced the overheating of the SF. The 0.5% salt solution in the OB produced the least overheated areas outside the deep target tumor compared with the other concentrations. The insertion of the intergluteal cleft (IGC) bolus could improve the temperature concentration of the deep target tumor. Conclusions: The use of OBs and the salt solution concentration in the OB were important to optimize the temperature distribution. IGC bolus might contribute to temperature optimization. Further studies with individualized numerical simulations in each patient are expected.

5.
J UOEH ; 42(3): 261-266, 2020.
Article in English | MEDLINE | ID: mdl-32879190

ABSTRACT

Radiation recall pneumonitis is a phenomenon in which a recall-triggering drug induces an acute inflammatory reaction in the lungs, corresponding to a previously irradiated area. Radiation recall reactions have been reported to occur following treatments with various cytotoxic anticancer agents and molecular-targeting drugs; however, only a few reports have described immune checkpoint inhibitor-induced radiation recall pneumonitis. We report a case of radiation recall pneumonitis induced by pembrolizumab in a patient with the postoperative local recurrence of non-small cell lung cancer. This case demonstrated that pembrolizumab might cause severe radiation recall pneumonitis, even after typical radiation pneumonitis has been resolved.


Subject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Antineoplastic Agents/adverse effects , Asymptomatic Diseases , Carcinoma, Non-Small-Cell Lung/therapy , Lung Neoplasms/therapy , Radiation Pneumonitis/etiology , Radiotherapy/adverse effects , Combined Modality Therapy , Humans , Neoplasm Recurrence, Local/drug therapy , Neoplasm Recurrence, Local/radiotherapy
6.
Org Lett ; 22(16): 6234-6238, 2020 Aug 21.
Article in English | MEDLINE | ID: mdl-32584583

ABSTRACT

We found that the α-boryl radical of potassium alkyltrifluoroborate shows higher reactivity compared to the α-boryl radicals of alkylboronic acid pinacol ester and alkyl N-methyl imidodiacetic acid (MIDA) boronate in the halogen atom abstraction step of atom-transfer radical addition (ATRA) between alkyl bromide and vinylborons. In this research, an ATRA of alkyl halides with potassium vinyltrifluoroborate furnished unique alkylborons, which are difficult to synthesize by other methods.

SELECTION OF CITATIONS
SEARCH DETAIL